Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-1
2009-010196-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Everolimus plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started Feb 2010; status: completed.
02
Drugs
everolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-010196-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010196-25.